Clinical Focus Target markets for collaboration or licensing include oncology and immunology with lead candidate milciclib (CDK and kinase inhibitor) in Phase II for thymic carcinoma and foralumab (fully human anti-CD3) in Phase II for autoimmune and inflammatory diseases; explore partnerships to accelerate clinical development and expand indications.

Intranasal Foralumab Leverage intranasal delivery route of foralumab for higher patient compliance and potential expansion into CNS and neurodegenerative applications evidenced by recent Phase II MS-related research; propose co-development or regional licensing deals in autoimmune and inflammatory indications.

Clinical Partnerships Active pipeline with multiple conference appearances and poster presentations indicates readiness to engage investors and potential CROs or pharma collaborators; propose sponsored research, co-development agreements, or strategic partnerships to accelerate trials.

Market Visibility Participation in major forums (World Parkinson Congress, BIO-Europe, Neuroscience Innovation Forum, ECTRIMS) suggests opportunities to assemble strategic messages for alliances, regional licensing, and access to specialty pharma networks focused on neurology and immunology.

Financial Position Revenue range is modest with a small employee base; identify opportunities for milestone-driven partnerships, co-funding, or grant collaborations to support ongoing Phase II programs and de-risk early-stage development for potential acquirers or partners.